FeesSafety
Pluang+

Hippo Holdings reports Q3 net income of $9M and 60% premium growth, raising 2026 profit forecast.

Company Fundamentals
29 Oct 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
Hippo Holdings reports Q3 net income of $9M and 60% premium growth, raising 2026 profit forecast.

Hippo Holdings Inc. reported a Q3 2026 net income of $9 million and adjusted net income of $20 million, with gross written premiums up 60% to $498 million. Despite a drop from last year's $98 million net income due to a one-time gain in 2025, the company improved profitability with a combined ratio of 98.4%. Growth was driven by expansion in Casualty and Commercial Multi-Peril lines, and Hippo raised its full-year 2026 adjusted net income guidance to $77-$80 million. The company emphasizes disciplined underwriting and portfolio diversification to sustain long-term profitable growth.

Hippo Holdings Inc.'s third quarter 2026 financial results provide context for readers. For those following Financials-sector US stocks on Pluang, 94 of 142 stocks rose and 43 fell today. Notable prices include RIOT at USD 14.01 with a 3.04% decline, TROW at USD 107.01 up 2.89%, and BMNR at USD 21.44 down 2.77%. This data is as of Oct 29, 2026 17:53 WIB.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App